Breast cancer (solid tumor): cross-border specialty drug access for international patients

Quick orientation

Breast cancer is the most commonly diagnosed cancer in women globally, with approximately 2.3 million new cases per year (Globocan 2022).

Typical age of onset. Most commonly diagnosed after age 40; younger-onset disease is more common in some populations.

Severity tiers. Severity depends on stage, histology, hormone receptor and HER2 status, and molecular profile.

Why specialty drugs for Breast cancer (solid tumor) are hard to access internationally

Multiple targeted therapies, antibody-drug conjugates, and PARP inhibitors are recent additions. Several newer agents including PI3K alpha inhibitors and CDK7 inhibitors are not yet broadly registered.

Treatments approved by the FDA

• Enhertu (trastuzumab deruxtecan) — FDA approval: 2019. Mechanism: HER2-directed antibody-drug conjugate. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt · Oman.
• Datroway (datopotamab deruxtecan) — FDA approval: 2025. Mechanism: TROP2-directed antibody-drug conjugate. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: UAE · Saudi Arabia · India · Kuwait · Egypt.
• Truqap (capivasertib) — FDA approval: 2023. Mechanism: AKT inhibitor for HR+ HER2- advanced breast cancer. Route: Oral. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: UAE · Saudi Arabia · India · Qatar · Egypt · Jordan.
• Itovebi (inavolisib) — FDA approval: 2024. Mechanism: PI3K alpha inhibitor for PIK3CA-mutated HR+ HER2- breast cancer. Route: Oral once daily. US WAC ballpark: Approximately USD 230,000 per year. Country pricing: UAE · India · Bahrain · Lebanon.
• Orserdu (elacestrant) — FDA approval: 2023. Mechanism: Oral selective estrogen receptor degrader for ESR1-mutated HR+ HER2- breast cancer. Route: Oral once daily. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: Saudi Arabia · Egypt.
• Hercessi (trastuzumab biosimilar) — FDA approval: 2024. Mechanism: HER2-directed monoclonal antibody biosimilar. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 60,000 to 90,000 per year. Country pricing: Jordan · Bahrain · Lebanon.
• Ziihera (zanidatamab-hrii) — FDA approval: 2024. Mechanism: HER2-directed bispecific monoclonal antibody. Route: Intravenous infusion every 2 to 3 weeks. US WAC ballpark: Approximately USD 230,000 per year. Country pricing: Saudi Arabia · Bahrain.

Cross-border pathways used for Breast cancer (solid tumor)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription
• Expanded Access Program (EAP)

What your physician needs to know

• Confirm hormone receptor, HER2, and molecular profile (PIK3CA, ESR1, BRCA, HRD).
• Document prior systemic therapy.
• Coordinate with multidisciplinary breast oncology team.
• Watch for class-specific adverse events including interstitial lung disease with ADCs.
• Plan supportive care concurrently.

Common questions

Which targeted therapy is right for my case?

Choice depends on molecular profile, prior therapy, and patient factors. Your oncologist decides.

Are these drugs available in my country?

Registration varies. We confirm by destination.

Can I switch lines of therapy?

Sequential therapy is common in metastatic disease. We support transitions.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Oncologist's prescription, pathology with biomarkers, imaging, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Breast cancer (solid tumor), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Breast cancer (solid tumor)

Reserved for you.